News & Events

Published On: 2/20/2020

TARGET-IBD Poster & Oral Presentation at ECCO

Earlier this month, TARGET attended the 15th annual Congress of European Crohn’s and Colitis Organisation (ECCO) event in Vienna, Austria. TARGET was selected to present two encores from the 2019 American College of Gastroenterology meeting.  

The first was accepted as a poster, “Oral Mesalamine Use in Crohn’s Disease After Implementation of the American College of Gastroenterology Guidelines: A TARGET-IBD Cohort Study”.  It was presented by Bruce Sands, MD, a TARGET-IBD steering committee Co-Chair and Chief of the Dr. Henry D. Janowitz Division of Gastroenterology at Mount Sinai.

The second was accepted as a digital oral presentation titled “Medication Use and Comorbidities Among Elderly as Compared to Younger Patients with Inflammatory Bowel Disease in the TARGET-IBD Cohort”It was also presented by Dr. Sands.

The focus of the talk was on characterizing inflammatory bowel disease-related medications in elderly patients. Notable findings were that mesalamine use was the most common medication among patients over 65 years of age (even for Crohn’s disease patients), and that use of anti-tumor necrosis factor alpha medications decreased in patients in the older age groups when compared to patients under 30 years of age. The presentation was additionally honored as the Best Digital Oral Presentation of Session 3.

You can find all of the presented TARGET-IBD posters on our Publications page.

About Target RWE

Target RWE is a leading health evidence solutions company that generates innovative real-world evidence (RWE) and provides scientific intelligence tools and solutions for pharmaceutical, biotechnology, and other healthcare partners. Specifically designed to address the complexities of the natural history of disease, the drug development process and treatments in real-world settings, Target RWE builds regulatory-grade clinical data sets and applies state of the science epidemiologic methods to produce RWE about patients with specific conditions, symptoms, and therapies used in usual clinical practice.

Target RWE's regulatory-grade data sets and evidence, modern epidemiological methods, and sound scientific principles rendered as software can be utilized to better health outcomes, inform patient health guidelines, and improve overall quality of care. For more information, visit www.targetrwe.com.

Contact:

Kayla Slake
Marketing Manager

kslake@targetrwe.com

984.234.0268 ext 205